67N0 Stock Overview
A biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genor Biopharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.12 |
| 52 Week High | HK$0.18 |
| 52 Week Low | HK$0.085 |
| Beta | 0.62 |
| 11 Month Change | 3.54% |
| 3 Month Change | -2.50% |
| 1 Year Change | -26.42% |
| 33 Year Change | -93.31% |
| 5 Year Change | n/a |
| Change since IPO | -93.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 67N0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.9% | -3.0% | -0.1% |
| 1Y | -26.4% | -19.4% | 2.3% |
Return vs Industry: 67N0 underperformed the German Biotechs industry which returned -18.9% over the past year.
Return vs Market: 67N0 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 67N0 volatility | |
|---|---|
| 67N0 Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 67N0's share price has been volatile over the past 3 months.
Volatility Over Time: 67N0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 104 | Feng Guo | www.genorbio.com |
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn’s disease, and fistulizing crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating breast cancer; and GB492, a stimulator of interferon genes in combination with GB226, which is under Phase 1/2 clinical trial to treat solid tumors. It also develops GB226, which is in Phase III clinical trial to treat 2L+ cervical cancer; in phase II trial to treat ASPS and r/r PMBCL; and in Phase I trial to treat 2L/3L+ EGFR+ NSCLC and 2L+ mCRC.
Genor Biopharma Holdings Limited Fundamentals Summary
| 67N0 fundamental statistics | |
|---|---|
| Market cap | €69.54m |
| Earnings (TTM) | -€86.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs 67N0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 67N0 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥674.36m |
| Earnings | -CN¥674.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 67N0 perform over the long term?
See historical performance and comparison